Eli Lilly and Co.LLY

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · lilly.com

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, that discovers, develops, manufactures, and markets medicines across therapeutic areas including diabetes, obesity, oncology, immunology, and neuroscience. Its leading products include Mounjaro and Zepbound (tirzepatide) for diabetes and obesity, Verzenio for breast cancer, and Taltz for autoimmune conditions. Lilly operates in more than 125 countries and invests heavily in research and development.

Key ratios

Operating cash flow growth

156.7%TTM

2025 90.7%2024 108.0%2023 -44.1%

EPS growth

94.8%TTM

2025 96.0%2024 101.9%2023 -15.9%

FCF / Sales

22.8%TTM

2025 13.8%2024 8.3%2023 2.3%

Net margin

33.5%TTM

2025 31.7%2024 23.5%2023 15.4%

ROA

19.4%TTM

2025 19.4%2024 14.9%2023 11.4%

ROE

101.2%TTM

2025 101.2%2024 84.3%2023 48.4%

Revenue growth

49.6%TTM

2025 44.7%2024 32.0%2023 19.6%

Recent news

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy 2026-06-26 · PR Newswire Lilly declares third-quarter 2026 dividend 2026-06-22 · PR Newswire

Track LLY in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer